Company Overview and News

10
Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

2018-08-15 247wallst
Each month brings new views from firms on Wall Street. This includes the actively followed RIC Report from Merrill Lynch, showing views on many sectors and many markets for the firm’s clients. The monthly RIC Report is quite favorable on the health care sector as an opportunity for investors.
PFZ AMGN MRK A ABBV 500680 PFE PFIZER ABBV

1
Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Thank you for joining the Cumberland Pharmaceuticals Second Quarter 2018 Financial Report and Company Update. Please note that this conference call is being recorded at the Company's request and will be archived on Cumberland's Web-site for one week from today's date. Now I would like to introduce Erin Smith, who is responsible for corporate relations at Cumberland. Erin, please go ahead.
AMGN CPIX

20
Top Research Reports: UnitedHealth, PepsiCo, Amgen & More

2018-08-14 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 12 major stocks, including UnitedHealth (UNH), PepsiCo (PEP) and Amgen (AMGN). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
FOX GD AMGN CQP LNG CVS CLH ABB 7018 PEP AMT CME ABLZF TXT UNH FOXA

3
Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release

2018-08-14 zacks
Merck & Co., Inc. (MRK - Free Report) stock has risen 4.2% since the company announced second-quarter earnings on Jul 27.
MRK AZN AMGN AZN INCY

2
Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why

2018-08-14 zacks
Allergan plc (AGN - Free Report) stock has risen 4.2% since it announced second-quarter earnings on Jul 26.
AMGN EDIT AGN

9
3 “Strong Buy” Stocks for the Week

2018-08-13 investorplace
Stocks entered the weekend on a sour note. Turkey currency woes were all the excuse needed to end the multi-day rally that had carried the S&P 500 within a whisker of all-time highs. But one day does not a downtrend make. My weekend scanning revealed many “strong buys” that deserve a top spots on your list of stocks to buy.
AMGN AAPL LULU

20
Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

2018-08-13 zacks
Eli Lilly & Company’s (LLY - Free Report) stock has risen 15% since it announced second-quarter earnings on Jul 24.
FOX ARMO AMGN TEVJF TEVA NVS TEVVF LMHA LMHB FOXA LM

10
Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2

2018-08-11 zacks
Spectrum Pharmaceuticals, Inc. (SPPI - Free Report) incurred an adjusted loss of 21 cents per share in the second quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 18 cents and the year-ago quarter loss of 11 cents per share.
SGEN GJV VRTX AMGN NWS NWSA SPPI

12
Roche: Details On Growing Through The Patent Cliff (Part 2 Of 2)

2018-08-09 seekingalpha
Roche has implemented what I view as a brilliant strategy to do more than survive the patent expirations of its Big 3 drugs.
AMGN BIIB ABBV PFE ABBV

8
5 Companies Making Giant Buybacks

2018-08-08 investorplace
Thanks to the Republican tax plan and increasing revenues, investors are seeing a bit more green in their pockets. That’s courtesy of rising buyback activity. So far, 2018 has been a record year for buybacks, with companies already authorizing $754 billion worth. However, given the continued jump to cash flows and balance sheets, analysts at Goldman Sachs estimate that we’ll actually hit the trillion-dollar mark in terms of buyback activity by the time the year ends.
AMGN V PKW TROW AAPL

9
Trump Forces Pharma to Face More Medicare Drug-Price Negotiation - Bloomberg

2018-08-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AMGN ABBV ABBV

4
Biopharma 2018: Growth At A Reasonable Cost (GARC)

2018-08-07 seekingalpha
The prospects for the biopharmaceutical industry, driven by new drug discovery, are extremely attractive. I discuss below the "GARC" stocks, Gilead, Amgen, Regeneron and Celgene.
AMGN CELG BLUE

1
Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up

2018-08-07 zacks
Radius Health, Inc. (RDUS - Free Report) reported encouraging results for the second-quarter of 2018, wherein loss was narrower than expected and sales beat estimates.
LLY AMGN GILD LLY RDUS

12
Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View

2018-08-07 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report) reported second-quarter 2018 adjusted earnings of $2.59 per share, significantly up from the year-ago figure of 67 cents. The bottom line also beat the Zacks Consensus Estimate of 93 cents.
SAGE AMGN SPPI LGNZZ ALDX LGND LGNYZ NVS LGNXZ LGNDZ WXXWY

11
Biogen Hits A Potential Home Run

2018-08-07 seekingalpha
Biogen's current product lineup is beginning to show its age, and a fresh injection of novel products may be necessary to jumpstart top-line revenue growth.
AMGN BIIB ABBV ABBV

Related Articles

RNVA: Rennova Health Analysis and Research Report

1h - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

CUSIP: 031162100